| Quality Life Services - New Castle | |
| 520 Friendship Street, New Castle, Pennsylvania 16101 | |
| (412) 654-7791 | |
| Name | Quality Life Services - New Castle |
|---|---|
| Location | 520 Friendship Street, New Castle, Pennsylvania |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 204 |
| Occupancy Rate | 45.74% |
| Medicare ID (CCN) | 395003 |
| Legal Business Name | Golden Hill Nursing And Rehab Lp |
| Ownership Type | For Profit - Partnership |
| NPI Number | 1679575989 |
| Organization Name | GOLDEN HILL NURSING AND REHAB LP |
| Address | 520 Friendship St, New Castle, PA 16101 |
| Phone Number | 724-654-7791 |
News Archive
Resistance training, some of it job-specific, was successful in getting 90 percent of workers with severe rotator cuff injuries back to work, the majority (75 percent) at their previous job, after traditional physical therapy had failed to do so.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
A new study from Joslin Diabetes Center has proven that certain biological protective factors play a large role in preventing diabetic kidney disease in certain people. The study was published today in Diabetes Care.
A new study performed by Boston Medical Center and faculty at the Boston University School of Medicine shows that urine drug testing can be a useful tool to treat patients with opioid use disorder in a primary care setting.
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Resistance training, some of it job-specific, was successful in getting 90 percent of workers with severe rotator cuff injuries back to work, the majority (75 percent) at their previous job, after traditional physical therapy had failed to do so.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
A new study from Joslin Diabetes Center has proven that certain biological protective factors play a large role in preventing diabetic kidney disease in certain people. The study was published today in Diabetes Care.
A new study performed by Boston Medical Center and faculty at the Boston University School of Medicine shows that urine drug testing can be a useful tool to treat patients with opioid use disorder in a primary care setting.
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 15.35 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9.4 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 62.33 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.53 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.66 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.84 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 55.22 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 20.13 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 41.35 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.72 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 12.36 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 20.93 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.65 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 73.27 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 95.34 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 36.92 | 82.93 |
News Archive
Resistance training, some of it job-specific, was successful in getting 90 percent of workers with severe rotator cuff injuries back to work, the majority (75 percent) at their previous job, after traditional physical therapy had failed to do so.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
A new study from Joslin Diabetes Center has proven that certain biological protective factors play a large role in preventing diabetic kidney disease in certain people. The study was published today in Diabetes Care.
A new study performed by Boston Medical Center and faculty at the Boston University School of Medicine shows that urine drug testing can be a useful tool to treat patients with opioid use disorder in a primary care setting.
› Verified 9 days ago
Quality Life Services - New Castle Location: 520 Friendship Street, New Castle, Pennsylvania 16101 Phone: (412) 654-7791 | |
Grove At New Castle, The Location: 715 Harbor Street, New Castle, Pennsylvania 16101 Phone: (724) 652-3863 | |
Edison Manor Nursing & Rehabilitation Center Location: 222 West Edison Avenue, New Castle, Pennsylvania 16101 Phone: (724) 652-6340 | |
Jameson Care Center Location: 3349 Wilmington Road, New Castle, Pennsylvania 16105 Phone: (724) 598-3300 | |
Haven Convalescent Home, Inc Location: 725 Paul Street, New Castle, Pennsylvania 16101 Phone: (724) 654-8833 |